Pod Insights Pharmacy Podcast Network Is Your Marketing Compliant | Marketing Vitals About this episode During the episode, Nicolle and Darshan discuss how marketing for pharmacies has become more challenging especially with GLP-1s, Compounding and AI. They highlight common mistakes pharmacy owners make when marketing their services and how to avoid them.
Transcript 0:05 Speaker 00 You are listening to the global network of podcasters dedicated to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
0:25 Speaker 01 Has your business's marketing flatlined?
0:29 Speaker 01 Find your pulse again with MarketingVitals, bringing you innovative and turnkey healthcare marketing solutions from industry experts who have developed a knack for solving problems. A co-hosted publication from GRX Marketing and Finch Marketing, sister companies that are passionate and knowledgeable about healthcare marketing.
0:47 Speaker 02 Hey, everyone. Welcome to another episode of MarketingVitals Podcast. I'm Nicole McClure, President of GRX and Finch Marketing, and so excited to be here today and talk to our guest. Love to introduce Darshan Khukani. He is a pharmacist, a regulatory and compliance attorney, a fellow podcaster. I think I got everything. Darshan, welcome to the show. Did I miss something?
1:16 Speaker 03 A few things, but I'm sure they'll be okay.
1:20 Speaker 03 I write various books. If you see the books behind me, I've written anywhere from one through six chapters in every single one of them. I teach at Drexel Law. I teach pharmaceutical marketing. I also, I speak all over the world on marketing and compliance and pharmacy-related issues, if you will. I just attended a conference last week in New York where I was presenting on it. I keynote various events and...
1:51 Speaker 03 I'm sure there's more, but I forgot.
1:53 Speaker 02 Just a few.
1:53 Speaker 03 Oh, I'm on board. I'm a board chair for multiple organizations. But yeah.
1:58 Speaker 02 Perfect. Well, so all of that experience definitely lends you to be a great guest on our show today. So I wanted to talk to you about just marketing for pharmacies and compliance. I feel like over the last couple of years, you know, from our perspective of working with a lot of independents, it's become much more complicated and challenging for them. Can you kind of talk about what you've seen on your side as far as how it's become more challenging?
2:33 Speaker 03 Oh, where do we start? Nicole, this, this is, this is sort of the multi-billion dollar question right now.
2:40 Speaker 02 Right.
2:41 Speaker 03 And pharmacies don't quite appreciate how big an issue it is. We can talk about a variety of different things at different levels, but we, we, let's, let's start with the first element, which is marketing that's connected to say, like, equipment manufacturers who are selling the equipment to pharmacies. A lot of those guys got in trouble because they were falsely billing Medicare and Medicaid. And essentially their marketing, the way they'd organize their marketing groups was set up in a way that these patients were receiving like orthopedic stuff or devices that they really didn't need.
3:25 Speaker 03 It was more of a churning game to see if they can bill Medicare and Medicaid for as much as they could. And it's one thing to do that if you're trying to help patients. It's another thing if it's basically just a route to bill Medicare and Medicaid. So if, if it's unnecessary, you end up paying a bunch of money for it. So if your pharmacy was involved in that process, you can get people into trouble. The second element that I've seen is sort of pharmacists who are involved in clinical research. And they were marketing their services in a way that it was less. About the research and more about the um more more about the sales process and and dispensing products.
4:08 Speaker 03 Um. And that came in two different forms. We'll talk about one form now and we'll talk about another form later. But tha- that first version landed landed up becoming um something that's targeted. People have gone to jail over it. Um. You had pharmacy technicians and pharmacists go to jail over that. So tha- that's number two. Then you had number three, which was compounding pharmacies. Um. And that's a whole other beast. Um. And and the reason you get
4:35 Speaker 03 mixed in this area is because compounding pharmacies are often doing a cash-based system. Um. So the traditional Medicare Medicaid got defrauded doesn't work in that scenario. You may have some state laws that kick in, but not at the federal level. However, patients are um challenged and and the uh because there there are other federal rules that kick in, for example, on transparency, on disclosure. So the FTC has has something to say about it. The FDA could take the position they have that it is false and misleading. Um. The state boards have pulled it have called it out multiple different times
5:20 Speaker 03 as um the the advertising tends to be uh noncompliant. Um. You you also have uh uh these pharmacies who would sort of say you can have any compounded medication you want as long as this one. So um we we used to see that a long time ago in like the DEA world, where pharmacists would compound specific medications and have pre-printed um prescription pads. And the doctor would just check off the one they wanted. Right. And and that was very common and that was seen to be problematic. Because you're not saying that the doctor doctor can customize anything. You're basically manufacturing and the doctor's choosing that medication. Well, we're doing the exact same thing
6:02 Speaker 03 in this uh in in in the GLP-1 world. Um. And that's becoming problematic because you're talking about drugs that are either Unapproved, you're talking about drugs that are approved, but this is not on a shortage list anymore. So it's not, it's not something you're going through a 503B for, or it's a 503A and you're adding something to quote unquote customize it, but it's a pre-printed sheet and you're going to add like, I don't know, vitamin B12 in it. And it's practically not going to have any, any commercial effect, any actual appreciable clinical effect. And that's come back to bike companies as well. And then you, you have this other variety
6:44 Speaker 03 of pharmacists who are basically going out there and making medications, so tablets. And they're pre, they're making tablets of semaglutide or tirzepatide. I don't think I've seen the tirzepatide version. I can't remember to be honest. When they, they don't have any of the appropriate filings for either a 505B1 or B2 with the FDA. So again, you're asking for all kinds of regulatory problems and consumer protection problems from lawyers and from the regulatory agencies and then the state bar, state boards as well. So, and these are just some of the examples of.
7:28 Speaker 02 Right, right.
7:29 Speaker 03 Yeah.
7:31 Speaker 02 Do you see then, because I know with GLP-1s, you know, at first there was, yeah, some litigation or just threats against pharmacies that were compounding. And now that it's, you know, not as popular as far as it is more commercially available, but pharmacies are still doing it. Do you still see that action that the FDA, other government groups are, are coming after pharmacies for those that are continuing to compound it then?
8:04 Speaker 03 Yes. So we're seeing that right now. We're seeing that with large companies as well because the government is looking for a scapegoat, someone that they are going to go after and making, make an example out of. I can't remember whether it was Ro or Hims, it's my memory. I'm sure we can double check that.
8:22 Speaker 02 I think it was Hims, yeah.
8:23 Speaker 03 I think it was Hims as well.
8:24 Speaker 02 Yeah.
8:25 Speaker 03 Where they are being referred to the Department of Justice for the claims that they were making. But again, we have to double check which company it was. And that's an example of the government taking it very, very seriously.
8:43 Speaker 03 But as you pointed out, this isn't the end. I think pharmacies have been fighting back and pharmacies are saying, why can't we make it? And the answer is very simple, because you didn't go through the approval process. If you want to go through the approval process, go ahead and sell it. But that's a different beast. I think that the next step is going to be peptides. And I think that's going to raise all kinds of new havoc that we simply don't know how to deal with. I was, again, at that conference last week, and people are still trying to figure out what, what to do with peptides because they're known to be unapproved products. So how do you make a compounded version of something whose API itself was never approved? And that's going to be problematic going forward. So we had some ideas
9:27 Speaker 03 and we'll see if anything lands out of them, but we'll see.
9:30 Speaker 02 Yeah. And the independent pharmacies that we work with, I mean, especially on GLP-1's compounding marketing, I mean, the biggest issue we see is they want to try to make false claims. And I think there's this bit of conception that, well, we're a small pharmacy, like, you know, FDA is not going to find out, or we're not going to get in trouble, that sort of thing. But I think it's just a slippery slope that they're trying to go down, you know, as this just continues to be an issue.
10:03 Speaker 03 So few different questions, concerns with this. So number one, in the end, what you're really going is, we have a highway with a bunch of cars speeding on it. How many people can the cops stop?
10:18 Speaker 02 Mm hmm.
10:18 Speaker 03 I don't know if I really want to find out.
10:19 Speaker 02 Great analogy, yeah.
10:21 Speaker 03 Um, and yes, theoretically, the cop could only stop one company at a time. Except the FDA is not as understaffed as you think. The FDA, if I, last time I checked, and we're going back several years at this point, the FDA had like 77,000 employees. Out of that, if I remember correctly, a thousand are in advertising and promotion, just Cedar. So that's OPDP. That's not counting the Office of Unapproved Drugs. That's not counting Applebee's. That's not counting CDRH. But it's, it's not an insignificant number. You then add on the,
10:59 Speaker 03 you, you add on the FTC, you add on the state attorney generals, you add on state, state board of pharmacy, you add on lawyers who are now going, you know what? Maybe a small pharmacy, someone I could ignore, but I can, I can go after Hims. I can go after Roe.
11:16 Speaker 02 Yeah.
11:17 Speaker 03 We're gonna see more, more of those guys. And once you do the Hims and the Rose and you succeed and you've got these multi-billion dollar companies, you're gonna go after smaller pharmacies as well.
11:26 Speaker 02 Yeah, you've set a precedent.
11:27 Speaker 03 So do you really want to be in a position where you're just a target? You know you're a target and you're, you're going to be targeted and you're just waiting for that right moment? Cause I would also argue that I don't know if your insurance will cover you. So you've spent a lot of time as a pharmacy owner, building your business, protecting your children, growing your pharmacy. For, and you're risking it now for what? For an extra, I don't know, $10,000 this, this year, $100,000 this year. I, I don't know, but the point being, I don't know if it's worth it. I don't, for me personally, it wasn't. I, I wouldn't risk my pharmacy license for that.
12:06 Speaker 02 Right, right.
12:09 Speaker 02 What are you seeing as far as like AI and compliance with pharmacy marketing? So, you know, we of course have a lot of clients that are like, will send us something. And clearly you can tell it's been run through AI. And I think AI has its purpose, but I have found in healthcare, it's inaccurate a lot. And so, but it's just like, we're taking this gold standard around it that, well, you know, AI told me, so it has to be 100% true. From a compliance standpoint, I guess, kind of what are you seeing on that side?
12:48 Speaker 03 So a couple of different things. So I think the first thing is, um, there, there's actually a manufacturer very recently, who used an AI as their compliance tool chest. And the FDA came in and they were like, what are you guys doing? And why don't you have this documentation filled out? And the guy literally said, because AI told me to. And why didn't you fill out this one? Because AI told me to. And the FDA went, no, that's not how any of this works. You, you don't get to blame AI for this. You need to have systems in place. Those systems need to work. AI can help you, but it does not eliminate the need for the systems. On top of that, the DOJ, the Department of Justice, has already come out and said that
13:33 Speaker 03 in the end, fraud using AI is still fraud.
13:37 Speaker 02 Right.
13:38 Speaker 03 So I, I've, and, and then there's the actual, and, and you say this as a marketer. I can only imagine what you see that's being generated by AI. Cause I can tell you the vast majority of stuff that I see. Number one, it's incredibly clocky as AI.
13:57 Speaker 02 Right.
13:57 Speaker 03 And you're just going, no, I mean, maybe about five years ago, this was glossy and cool. But now it just looks like something, someone's just gonna scroll over. I, cause I know if I see something from AI, I don't wanna read it anymore.
14:11 Speaker 02 Right.
14:12 Speaker 03 I, if I can even, if I even believe or think, and I could be wrong, that it was written by AI, I don't wanna read it anymore. I sometimes have to use AI as like an initial generation point and then clean it up. And then honestly, even make some mistakes in there. Just, like, I may know that it's a mistake, and I say mistake in terms of like, um, formatting, not in terms of content. Um, but the idea being that people wanna read something human.
14:42 Speaker 02 Right.
14:42 Speaker 03 And, and that's just purely from a marketing standpoint. From a compliance standpoint, you're still responsible for what it says. The, the fines and penalties, I, I have a friend, um, and you probably know him. Uh, he's working at a pharma company. And, uh, he, he informed me that, um, he's surprised how long approval takes in a pharma company compared to a pharmacy. He's like, oh my God, it takes like three weeks to get a document approved just so I can share it. I don't understand why. And I had to explain the concept of MLR to him, of medical legal regulatory review. Cause if you're gonna put something out and people are gonna believe you,
15:24 Speaker 03 the fines and penalties that go along with it are significantly more. If you're a pharmacy and you were going, no one's gonna notice that anymore. Well, guess what? You're operating in one of the most profitable systems there is.
15:38 Speaker 02 Hmm.
15:39 Speaker 03 And yeah, it's very much an area that people care about and, and you might get sued for that. So compliance is
15:47 Speaker 03 very much an issue. I, I see mistakes. I, I can't think of an AI document or write-up I've seen that has had no mistakes. And this is going back now four or five years. Like you always, it either has something off about the tone, the information itself, like it's, it's like it. It understood the information, but not quite. And that was my experience with it. Like you, you got to like, you'd get a solid C minus. But I can't get you to a C yet.
16:20 Speaker 02 Right. Well, and I think the irony with, you know, independents especially is you're trying to come across as like this personable.
16:29 Speaker 03 Yeah.
16:29 Speaker 02 You know, in the community, that sort of thing. And then the content that you're putting out on your website, social media is that messaging is not matching when you're using AI. So you're just losing people, like you said, just scrolling past.
16:44 Speaker 03 I'll give you, I've never seen this version, but this is an example of the type of mistakes you'd see. Come to your local pharmacy at the corner of Erie and Fenton. And, and we'll give you blah, blah, blah. Except there's no Erie and Fenton in your neighborhood. I would totally be gaslit going, I don't know where Erie and Fenton is. Maybe I just don't live here. Or maybe I like, it's an area I haven't been to, except AI generated that. And anyone who's not looking is going, that seems okay.
17:12 Speaker 02 Right.
17:13 Speaker 03 But it feels like AI seems to gaslight you more than it should. But that's just my take.
17:20 Speaker 02 Yeah. It also just seems like an easy avenue for kind of back to these lawsuits, you know, for lawyers just to start perusing websites for, you know, copyrighted photos that people are using that AI was like, use this one. It's okay. Or, you know, pulling content from websites without sourcing it.
17:43 Speaker 02 Just seems like a dangerous road to go down. For any business pharmacies, you know, especially, I think.
17:52 Speaker 03 A hundred percent agree with you. I think the the way it works, and most people haven't read the terms of service. I actually tried to, this is going back probably over three years. I haven't re-reviewed, I should probably do that at some point. But I tried to look at what each tool gives you.
18:11 Speaker 03 And I'm going to get the order of these mixed up and who goes with what. I might get mixed up, but the general thrust remains the same. Which is, I want to say OpenAI says that you own what I own. So whatever, if you put in a prompt, you own what I own. So this way you can have control of that. Except what they don't tell you is that OpenAI got sued because they don't own anything.
18:33 Speaker 02 Right.
18:34 Speaker 03 They stole it.
18:35 Speaker 02 Yeah.
18:35 Speaker 03 Okay. Then I want to say Anthropic says you own the right to the prompts. Well, no shit, I own the right to the prompts. I'm the one to put it in. I want the everything else that.
18:48 Speaker 02 I hope I own those.
18:51 Speaker 03 And then there's the third one. And this is again, going back a few years, but Google Gemini, I think, said, it was just silent on it. It didn't say who owned anything. So my point is, these companies are being staffed by very, very expensive, very, very good lawyers. They're not taking the liability. So guess who is? You are. So keep that in mind as you continue as well.
19:18 Speaker 02 I'm just gonna cut that little snippet and just have it as a bite for when we get stuff from clients that we're like, no, this is why we're saying no.
19:32 Speaker 03 It's, yeah.
19:35 Speaker 02 Any other kind of common mistakes that you, you know, when working with pharmacies, you see that they're making? For us, it's like just, you know, not adding the proper disclaimers, trying to make claims that aren't accurate. But I guess anything else that kind of sticks out to you that people should be aware of, that they should probably already be aware of, but maybe aren't paying attention to?
20:04 Speaker 03 I can think of several. One is a disclaimer doesn't let you, it's not a get out of jail free card.
20:11 Speaker 02 Right.
20:12 Speaker 03 So if you are a pharmacy that's using disclaimers, you'll see this often. And I've seen that you make this fantastic claim, this drug is, I'm making this up. Or maybe I'm not. You might see compounded medications that are, that have these fantastic claims along with it. It's completely unapproved. And you're, um, and you think you're going to get away with it because why not? Except that might come back to bite you and you can't just go, oh, this has not been approved by the FDA. Well, no shit, it hasn't, excuse my language, but no crap. It's, it's not been approved by the FDA. So number one, keep track of those. Off label may be appropriate in very specific situations.
20:56 Speaker 03 This is not that situation. Talk, talk to your lawyer. Fine, I'm not your lawyer. This is not legal advice.
21:03 Speaker 02 Right.
21:03 Speaker 03 Keep track of what applies. Another one that pops in mind is privacy. In the, in the context of, uh, privacy, there is, how are you coming up for the data? For example, are you putting the data into AI? I see that happen every single, every so often as well. That's a violation of multiple, multiple laws. Then there is the actual of following CAN spam laws, TCPA laws. If you're texting people, uh, following, uh, the do not call list. I keep track of that. TCPA is probably the most litigated lawsuits in the world right now. So.
21:42 Speaker 02 With texting and stuff?
21:43 Speaker 03 Yeah, with texting and stuff.
21:44 Speaker 02 Yeah.
21:45 Speaker 03 And people don't know that they're supposed to register, get it all done. And, um, it's hugely problematic. So I, I think there are loads of areas that pharmacists need to comply with. And everyone seems to operate with the, I'm just going to be the, I'm going to be the Ford Fiesta driving on, on the highway. But I know there's a Mercedes driving on as well. So I hope they catch the Mercedes and not the Ford Fiesta. But you know what? Every so often, the Mercedes is still far behind. They can still catch the Ford Fiesta as well. God, I hope there's a, there's a version called a Ford Fiesta, but yeah.
22:19 Speaker 02 Yeah. It's a little car. Yeah.
22:23 Speaker 03 Yeah.
22:25 Speaker 02 No, those are all great points. And I mean, something so with websites and social media specifically, like a recent development of, um, ADA changes and making sure, you know, your stuff is compliant and. We're still seeing some of that where pharmacies don't want to pay to add the widget to the website. And kind of going back to what you were saying with GLP1s, it's like, what's your comfort level? This little widget is like 50 bucks a month. If you happen to get sued, it's going to be thousands of dollars that you're going to have to potentially pay out. So sometimes I think it's hard for them to just want to take that step, either they're
23:09 Speaker 02 paying for it, or making sure everything is on the up and up.
23:13 Speaker 03 I think another area that I think both of us would probably end up advising a lot of these clients about is make sure that your insurance has appropriate coverage for this stuff. You might find out that your insurance doesn't cover you, or that the limits are very, very low. And go talk to your insurance provider and make sure that they're covering you properly. And don't let them sell you the cheapest thing in the world, because the cheapest thing doesn't protect you. Look for the one that's right for you. So I have nothing to do with insurance. I'm happy to refer you if you want, but it has nothing to do with me. But I tell this to all my clients, whether it's pharma, pharmaceutical companies, medical device companies, or pharmacies, the goal of insurance is always to protect
23:56 Speaker 03 you. And if you don't have the right coverage, you're not being covered. And that's problematic.
24:01 Speaker 02 Yeah, excellent point. Well, anything else to share with our listeners before we wrap it up?
24:08 Speaker 03 No, I think we covered a lot of ground. If people like what we're saying, they can come back, talk to me, talk to you. And I'm sure they'll get some more information. And if you need to reach me, you can reach me at Darshan, D-A-R-S-H-A-N, at kulkarani lawfirm.com. That's K-U-L-K-A-R-N-I lawfirm.com. Or you can reach Nicole. And she's very, very approachable, and obviously very, very smart. So you should reach out to her as well.
24:38 Speaker 02 Well, thank you for being a guest on the show. It was great to chat with you.
24:41 Speaker 03 Thank you again, Nicole. I appreciate it.
24:43 Speaker 02 And if you need to reach me, you can find me at GRXmarketing.com or finchmarketing solutions.com. Thanks for joining us for another episode of Marketing Vitals Podcast, part of the Pharmacy Podcast Network.
Previous Understanding Mineral Deficiency & Metal Toxicity with Jeff Lioon | The Holistic Pharmacy Podcast Next Estrogen and Alcohol | Sex PharmD Page updated November 14, 2026 · transcript and summary are machine-generated